Related Experiment Video

Updated: Jan 7, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K

Exploring KAT6 as a therapeutic target in breast cancer: epigenetic approaches for precision medicine

Cyril Roussel-Simonin1,2, Aranzazu Fernandez-Martinez3,4,5, Sophie Postel-Vinay3,4,6

  • 1Department of Medical Oncology, Gustave Roussy Cancer Center, Villejuif, France. Cyril.roussel-simonin@gustaveroussy.fr.

NPJ Breast Cancer
|December 19, 2025
PubMed

Insights

Lysine acetyltransferase 6 (KAT6A/B) are key regulators in hormone receptor-positive breast cancer. Inhibiting KAT6A/B shows therapeutic potential for overcoming treatment resistance and improving patient outcomes.

Area of Science:

  • Oncology
  • Epigenetics
  • Molecular Biology

Background:

  • Hormone receptor-positive (HR+) breast cancer is a leading cause of cancer mortality in women.
  • Treatment resistance remains a major challenge despite advances in targeted therapies.
  • Epigenetic dysregulation, including histone acetylation, is implicated in breast cancer progression and resistance.

Purpose of the Study:

  • To review the role of Lysine acetyltransferase 6 (KAT6A/B) in HR+ breast cancer.
  • To highlight KAT6A/B as potential therapeutic targets.
  • To discuss the implications of KAT6 inhibition for overcoming treatment resistance.

Main Methods:

  • Review of preclinical evidence on KAT6A/B function and inhibition.
  • Analysis of molecular mechanisms of KAT6A/B in gene regulation and oncogenic pathways.
  • Exploration of challenges and prospects in epigenetic drug development for breast cancer.

Main Results:

  • KAT6A/B regulate histone acetylation, chromatin structure, and gene expression.
  • These enzymes are involved in transcriptional activation, chromatin remodeling, and cellular senescence.
  • Preclinical studies support the therapeutic potential of KAT6 inhibitors.

Conclusions:

  • KAT6A/B are promising therapeutic targets for HR+ breast cancer.
  • KAT6 inhibition may offer a strategy to overcome treatment resistance.
  • Biomarker-driven approaches and combination therapies are crucial for clinical success.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.0K
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K